---
title: "Novo Nordisk A/S Announces Availability of Disclosure on Executive Share Transactions"
description: "Novo Nordisk A/S has disclosed the sale of 28,710 shares by Executive Vice President Ludovic Helfgott at a price of DKK 295.00 per share, totaling DKK 8,469,450.00. The transaction occurred on August "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/252255739.md"
published_at: "2025-08-08T13:52:23.000Z"
---

# Novo Nordisk A/S Announces Availability of Disclosure on Executive Share Transactions

> Novo Nordisk A/S has disclosed the sale of 28,710 shares by Executive Vice President Ludovic Helfgott at a price of DKK 295.00 per share, totaling DKK 8,469,450.00. The transaction occurred on August 7, 2025, at Nasdaq Copenhagen. For further details, visit novonordisk.com. This information was published via EDGAR by Novo Nordisk A/S on August 08, 2025.

Novo Nordisk A/S has published a disclosure regarding the sale of shares by Ludovic Helfgott, an Executive Vice President at the company. The transaction involved the sale of 28,710 shares at a price of DKK 295.00 per share, totaling DKK 8,469,450.00. The transaction took place on August 7, 2025, at Nasdaq Copenhagen. For more information, visit novonordisk.com (here). Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Nordisk A/S published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-25-005210), on August 08, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [NVO.US - Novo Nordisk AS](https://longbridge.com/en/quote/NVO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| GLP-1 drugs may cause scurvy in patients | GLP-1 weight loss drugs, including Ozempic and Wegovy, are linked to cases of scurvy, a rare illness caused by vitamin C | [Link](https://longbridge.com/en/news/275772745.md) |
| Correction to Novo Nordisk TV Ad Article on Feb. 9 | Angela Muñoz is director of regulatory affairs at Novo Nordisk. "Novo Nordisk TV Ad for Oral Wegovy Has Misleading Claim | [Link](https://longbridge.com/en/news/275669553.md) |
| Novo Nordisk to Manufacture Wegovy in Ireland Facility | Novo Nordisk to Manufacture Wegovy in Ireland Facility | [Link](https://longbridge.com/en/news/275789396.md) |
| Novo Nordisk Aims To Start Selling Its Weight-Loss Blockbuster Wegovy In Vials - Bloomberg News | NOVO NORDISK AIMS TO START SELLING ITS WEIGHT-LOSS BLOCKBUSTER WEGOVY IN VIALS - BLOOMBERG NEWS | [Link](https://longbridge.com/en/news/275654518.md) |
| Novo Nordisk CFO Karsten Munk Knudsen Sells Shares Worth Over DKK 8.3 Million | Novo Nordisk A/S announced that CFO Karsten Munk Knudsen sold 26,246 shares for DKK 8.3 million at DKK 315.60 each and 3 | [Link](https://longbridge.com/en/news/275652909.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.